Immunotoxins in the Therapy of Leukemias and Lymphomas

References

• Dillman R, Shawler D, Dillman J, et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2: 881–891
   PubMed Web of Science ®Google Scholar
• Dillman R, Shawler D, Sobol H, et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59: 1036–1045
   PubMed Web of Science ®Google Scholar
• Foon K, Schroff R, Bunn P, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085–1093
   PubMed Web of Science ®Google Scholar
• Sears H, Herlyn D, Steplewski Z, et al. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45: 5910–5913
   PubMed Web of Science ®Google Scholar
• Oldham R, Foon K, Morgan A, et al. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous infusion. J Clin Oncol 1984; 2: 1235–1244
   PubMed Web of Science ®Google Scholar
• Olsnes S, Ferrandez-Puentes C, Carrasco L, et al. Ribosome inactivation by the toxic lectins abrin and ricin: Kinetics of the enzymic activity of the toxin-A chains. Eur J Biochem 1975; 60: 281–288
   PubMedGoogle Scholar
• Eikland Olsnes K. S., Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 1980; 126: 321–326
   PubMed Web of Science ®Google Scholar
• Pappenheimer A. Diphtheria toxin. Ann Rev Biochem 1977; 46: 69–94
   PubMed Web of Science ®Google Scholar
• Olsnes S, Refnes K, Pihl A. Mechanism of action of the toxic lectins abrin and ricin. Nature 1974; 249: 627–631
   PubMed Web of Science ®Google Scholar
• Irving J. Pokeweed antiviral protein. Pharmacol Ther 1983; 21: 371–387
   PubMed Web of Science ®Google Scholar
• Barbieri L, Strip F. Ribosome-inactivating proteins from plants: Properties and possible uses. Cancer Surveys 1982; 1: 489–520
   Google Scholar
• Jansen F, Blythman H, Carriere D, et al. Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 1982; 62: 185–216
   PubMed Web of Science ®Google Scholar
• Frankel A E, Houston LL. Immunotoxin therapy of cancer. Monoclonal Antibodies in Clinical Chemistry, R Carrano, J Douillard. Marcel Dekker, New York, in press
   Google Scholar
• Gould B, Borowitz M, Groves E, et al. Phase I study of an antibreast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 1989; 81: 775–781
   PubMed Web of Science ®Google Scholar
• Weiner L, O'Dwyer J, Kitson J, et al. A phase I evaluation of the ricin A chain anti-breast carcinoma immunoconjugate 260F9-MAb-rRA. Cancer Res, in press
   Google Scholar
• Rodvien R, Grant K, Durrant L, et al. Phase I study of monoclonal antibody-ricin A chain immunotoxin in metastatic colon cancer. Proc Am Soc Clin Oncol 1988; 7: 427A
   Google Scholar
• Byers V, Rodvien R, Grant L, . Phase I study of monoclonal antibody-ricin A chain immunotoxin in metastatic colon cancer. Proceedings International Symposium on Immunotoxins., A Frankel, et al. Durham, 1988; 53
   Google Scholar
• Spitler L, del Rio M, Khentigan A, et al. Therapy of patients with malignant melanoma using a monoclonal antibody-ricin A chain immunotoxin. Cancer Res 1987; 47: 1717–1723
   PubMed Web of Science ®Google Scholar
• Hertler A, Schlossman D, Borowitz M, et al. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin-monensin. Int J Cancer 1989; 43: 215–219
   PubMed Web of Science ®Google Scholar
• Blakey D, Thorpe P. Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxin. Immunotoxins, A Frankel. Kluwer Academic, Boston 1988; 457–473
   Google Scholar
• Bourrie B, Casellas P, Blythman H, et al. Study of the plasma clearance of antibody-ricin-A-chain immunotoxins: Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur J Biochem 1986; 155: 1–10
   PubMedGoogle Scholar
• Bjorn M, Ring D, Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 1985; 45: 1214–1221
   PubMed Web of Science ®Google Scholar
• Press O, Vitetta E, Farr A, et al. Evaluation of ricin A chain immunotoxins directed against human T-cells. Cell Immunol 1986; 102: 10–20
   PubMed Web of Science ®Google Scholar
• Laurent G, Kuhlein E, Casellas P, et al. Determination of the sensitivity of fresh leukemic cells to immunotoxin. Cancer Res 1986; 46: 2289–2294
   PubMed Web of Science ®Google Scholar
• Myers C, Thorpe P, Ross W, et al. An immunotoxin with therapeutic potential in T cell leukemia: WT1-RTA. Blood 1984; 63: 1178–1185
   PubMed Web of Science ®Google Scholar
• Bregni M, Siena S, Formosa D, . Anti-human B-cell saporin immunotoxins specific for CD19 and CD22 B lineage antigens. Proceedings International Symposium on Immunotoxins., A Frankel, et al. Durham, 1988; 16
   Google Scholar
• Ghetie M, May R, Till M, et al. Evaluation of ricin A chaincontaining immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 1988; 48: 2610–2617
   PubMed Web of Science ®Google Scholar
• Uckun F, Ramakrishnan S, Houston L. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. J Immunol 1985; 134: 2010–2016
   PubMed Web of Science ®Google Scholar
• Fauser A, Shustik C, Langleben A, et al. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease. Clin Invest Med 1988; 11: 40–46
   PubMed Web of Science ®Google Scholar
• Martin P, Hansen J, Torok-Storb B, et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 437–444
   PubMed Web of Science ®Google Scholar
• Vallera D. Immunotoxins for ex vivo bone marrow purging in human bone marrow transplantation. Immunotoxins, A Frankel. Kluwer Academic, Boston 1988; 515–535
   Google Scholar
• Filipovich A, Vallera D, Youle R, et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. Transplantation 1987; 44: 62–69
   PubMed Web of Science ®Google Scholar
• Martin P, Hansen J, Buckner C, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic bone marrow grafts. Blood 1985; 66: 664–672
   PubMed Web of Science ®Google Scholar
• Mitsuyasu R, Champlin R, Gale, et al. Depletion of T-lymphocytes from donor marrow for the prevention of graft-versus-host disease following bone marrow transplantation: A prospective randomized double blind trial. Ann Intern Med 1986; 105: 20–26
   PubMed Web of Science ®Google Scholar
• Champlin R, Gale R. Bone marrow transplantation for acute leukemia: Recent advances and comparison with alternative therapies. Semin Hematol 1987; 24: 55–67
   PubMed Web of Science ®Google Scholar
• Fitzgerald D. The use of recombinant Pseudomonas exotoxin in the development of conjugates directed against the interleukin-2 receptor. Proceedings Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer., R. Dillman, I. Royston. San Diego 1988
   Google Scholar
• Hertler A, Schlossman D, Borowitz M, et al. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Resp Modif 1988; 7: 97–113
   PubMedGoogle Scholar
• Royston I, Majda J, Baird S, et al. Human T cell antigens defined by monoclonal antibodies: the 65,000 dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol 1980; 125: 725–731
   PubMed Web of Science ®Google Scholar
• Casellas P, Bourrie B, Gros P, et al. Kinetics of cytotoxicity induced by immunotoxins: Enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem 1984; 259: 9359–9364
   PubMed Web of Science ®Google Scholar
• Casellas P, Jansen F. Immunotoxin enhancers. Immunotoxins, A. Frankel. Kluwer Academic, Boston 1988; 351–368
   Google Scholar
• Le Maistre C, Frankel A, Kornfeld S, et al. Phase I/II study of a pan-T-cell immunotoxin (IT) in cutaneous T-cell lymphoma (CTCL). Blood 1989; 74: 601A
   Google Scholar
• Byers V, Henslee J, Kernan N, . Therapeutic response to a pan-T-lymphocyte monoclonal antibody-ricin A chain immunotoxin in steroid refractory graft versus host disease (GvHD). Proceedings International Symposium on Immunotoxins., A Frankel, et al. Durham, 1988; 50
   Google Scholar
• Kernan N. Evaluation of anti-T cell immunotoxin in treatment of chronic graft-versus-host disease. Proceedings Third International Conference on Monoclonal Antibody Conjugates for Cancer., R. Dillman, I. Royston. San Diego 1988; 16
   Google Scholar
• Byers V, Henslee J, Antin J, et al. Safety and therapeutic response to a pan-T-lymphocyte monoclonal antibody ricin A chain immunotoxin in graft versus host disease (GVHD). Proc Am Soc Clin Oncol 1988; 7: 734A
   Google Scholar
• Kernan N, Byers V, Scannon P, et al. Treatment of steroid resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. JAMA 1988; 259: 3154–3157
   PubMed Web of Science ®Google Scholar
• Leonard J, Wong Q, Kaplan N, et al. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates. Cancer Res 1985; 45: 5263–5269
   PubMed Web of Science ®Google Scholar
• Nadler L, Breitmeyer J, Coral F, et al. Anti-B4 blocked ricin immunotherapy for patients with B cell malignancies: Phase I trial of bolus infusions. Blood 1989; 74: 449A
   Google Scholar
• Ghetie M, May R, Till M, et al. Evaluation of ricin A-chain immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 1988; 48: 2610–2617
   PubMed Web of Science ®Google Scholar
• Shen G, Li J, Ghetie M, et al. Evaluation of four CD22 antibodies as ricin A-chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int J Cancer 1988; 42: 792–797
   PubMed Web of Science ®Google Scholar
• Engert A, Burrows F, Jung W, et al. Evaluation of ricin A-chain-containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin's disease. Cancer Res, in press
   Web of Science ®Google Scholar
• Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly detected small cell population. Int J Cancer 1982; 30: 445–459
   PubMed Web of Science ®Google Scholar
• Chittal S, Caveriviere P, Schwarting R, et al. Monoclonal antibodies in the diagnosis of Hodgkin's disease: The search for a rational plan. Am J Surg Path 1988; 12: 9–21
   PubMed Web of Science ®Google Scholar
• Stein H, Mason D, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Sternberg-Reed cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858
   PubMed Web of Science ®Google Scholar
• McIntosh D, Edwards D, Cumber A, et al. Ricin B chain converts a non-cytotoxic antibody-ricin A chain conjugate into a potent and specific cytotoxic agent. FEBS Lett 1983; 164: 17–20
   PubMed Web of Science ®Google Scholar
• Vitetta E, Cushley W, Uhr J. Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells. Proc Natl Acad Sci (USA) 1983; 80: 6332–6335
   PubMed Web of Science ®Google Scholar
• Greenfield L, Johnson V, Youle R. Point mutations in diphtheria toxin separated binding from entry and amplify immunotoxin selectivity. Science 1987; 238: 535–539
   Google Scholar
• Kondo T, Fitzgerald D, Chaudhary V, et al. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem 1988; 263: 9470–9475
   PubMed Web of Science ®Google Scholar
• Hudson T, Neville D. Enhancement of immunotoxin action: Manipulation of the cellular routing of proteins. Immunotoxins, A. Frankel. Kluwer Academic, Boston 1988; 371–389
   Google Scholar
• Akiyama S, Seth P, Pirker P, et al. Potentiation of cytotoxic activity of immunotoxins on cultured human cells. Cancer Res 1985; 45: 1005–1007
   PubMed Web of Science ®Google Scholar
• Murphy J, Bishai W, Borowski M, et al. Genetic construction, expression, and melanoma selective cytotoxicity of a diphtheria toxin-related α-melanocyte stimulating hormone fusion protein. Proc Natl Acad Sci (USA) 1986; 83: 8258–8262
   PubMed Web of Science ®Google Scholar
• Chaudhary V, Fitzgerald D, Adhya S, et al. Activity of a recombinant fusion between transforming growth factor α and Pseudomonas toxin. Proc Natl Acad Sci (USA) 1987; 84: 4538–4542
   PubMed Web of Science ®Google Scholar
• Loberboum-Galski H, Fitz Gerald D, Chaudhary V, et al. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc Natl Acad Sci (USA) 1988; 85: 1922–1926
   PubMed Web of Science ®Google Scholar
• Chaudhary V, Mizukami T, Fuerst TR, et al. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 1988; 335: 369–372
   PubMed Web of Science ®Google Scholar
• Hertler A, Schlossman D, Borowitz M, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: Studies in rhesus monkeys. Cancer Immunol Immunother 1989; 28: 59–66
   PubMed Web of Science ®Google Scholar
• Durrant L, Byers V, Scannon P, et al. Human immune response to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clin Exp Immunol 1989; 75: 258–264
   PubMed Web of Science ®Google Scholar
• Hertler A, Spitler L, Frankel A. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv 1988; 4: 245–253
   Google Scholar
• Lo Buglio A, Wheeler R, Leavitt R, . Pharmacokinetics and immune response to chimeric mouse/human monoclonal antibody (Ch-17–1A) in man. Proceedings International Symposium on Immunotoxins., A. Frankel, et al. Durham, 1988; 59
   Google Scholar
• Sehon A. A method for overcoming the immunogenicity of immunotoxins. Proceedings International Symposium on Immunotoxins., A. Frankel. Durham, 1988; 58
   Google Scholar
• Moolten F, Cooperband S. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science 1970; 169: 68–70
   PubMed Web of Science ®Google Scholar